ABPI embraces proposals for pharma’s growth ahead of UK elections
The UK pharmaceutical industry body has invited proposals on economic investment, support for manufacturing, clinical trials and R&D.
List view / Grid view
The UK pharmaceutical industry body has invited proposals on economic investment, support for manufacturing, clinical trials and R&D.
To drive environmental sustainability in pharma, EFPIA strives “to go beyond compliance on the targets set within the various EU legislative requirements as part of the EU Green Deal initiatives under the Zero Pollution, Circular Economy and Climate Action plans”.
The formulation was developed through a single emulsion solvent evaporation technique and offers new delivery approach which could improve patient compliance, the paper stated.
Experts at IP firm Finnegan discuss if the pharmaceutical industry is ready for the innovation and technologies that digitalisation and automation will bring, and whether these advances are a threat or ally to intellectual property rights in the sector.
Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology, Johnson & Johnson Innovative Medicines, offers insight into the promising evidence of cell therapies and biologic-based treatments for patients with multiple myeloma.
The new installation increases capacity at WuXi Biologics’ Hangzhou manufacturing facility from 8,000L to 23,000L.
At ACHEMA 2024, IMA Pharma will showcase its latest innovations, offering a range of advanced pharmaceutical product packaging and processing technology solutions.
Research suggests that the process spectroscopy market will gain a compound annual growth rate (CAGR) of 5.33 percent by 2033.
The chromatographic method uses ethanol as a solvent and as such, provides an environmentally-friendly approach, the paper stated.
The European Commission (EC) has granted Biogen its third rare disease treatment approval in the European Union.
A novel late-phase clinical candidate for diabetic macular edema and neovascular age-related macular degeneration will be developed as part of the proposed agreement.
Dr Maria Escolar, Chief Medical Officer, Forge Biologics, explores the advantages of the company’s novel AAV gene therapy for Krabbe disease, which could help to overcome some of the immune and safety challenges the gene therapy sector is facing.
A sustainable drug delivery method based on the biopolymer lignin could offer applications in anti-cancer therapies, research suggests.
Research suggests that the ampoules packaging market will see a seven percent compound annual growth rate (CAGR) between 2024 and 2033.
The research on nanomedicines investigated the intrinsic radiothermal emission of nanodrugs using a novel method.